Steffan T Nawrocki
Overview
Explore the profile of Steffan T Nawrocki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
9047
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carew J, Espitia C, Sureshkumar S, Carrera Espinoza M, Gamble M, Wang W, et al.
Cancer Lett
. 2025 Feb;
613:217496.
PMID: 39892703
Repurposing FDA approved drugs with off-target autophagy inhibition such as chloroquine/hydroxychloroquine (CQ, HCQ) has produced modest anticancer activity in clinical trials, due in part, to a failure to define predictive...
2.
Nawrocki S, Espitia C, Carrera Espinoza M, Gamble M, Sureshkumar S, Chang M, et al.
Clin Transl Discov
. 2024 Aug;
4(4).
PMID: 39100646
Patients with breast tumors that metastasize to the brain have limited treatment options and a very poor prognosis. More effective therapeutic strategies are desperately needed for this patient population. Recent...
3.
Nawrocki S, Espitia C, Carrera Espinoza M, Jones T, Gamble M, Sureshkumar S, et al.
Clin Transl Med
. 2024 Apr;
14(4):e1662.
PMID: 38658768
No abstract available.
4.
Chang M, Gao F, Gnawali G, Xu H, Dong Y, Meng X, et al.
J Med Chem
. 2024 Apr;
67(9):7301-7311.
PMID: 38635879
Although the selective and effective clearance of senescent cancer cells can improve cancer treatment, their development is confronted by many challenges. As part of efforts designed to overcome these problems,...
5.
Ogbuji V, Paster I, Recio-Boiles A, Carew J, Nawrocki S, Chipollini J
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201559
Urothelial carcinoma (UC) is the most common form of bladder cancer (BC) and is the variant with the most immunogenic response. This makes urothelial carcinoma an ideal candidate for immunotherapy...
6.
Nawrocki S, Olea J, Villa Celi C, Dadrastoussi H, Wu K, Tsao-Wei D, et al.
Clin Cancer Res
. 2023 Oct;
29(24):5087-5103.
PMID: 37812476
Purpose: Our preclinical studies showed that the oncolytic reovirus formulation pelareorep (PELA) has significant immunomodulatory anti-myeloma activity. We conducted an investigator-initiated clinical trial to evaluate PELA in combination with dexamethasone...
7.
Jones T, Espitia C, Chipollini J, Lee B, Wertheim J, Carew J, et al.
Cancer Res Commun
. 2023 Mar;
3(2):245-257.
PMID: 36860653
Significance: Cisplatin therapy is associated with significant nephrotoxicity, which limits its clinical use. Here we demonstrate that NEDDylation inhibition with pevonedistat is a novel approach to selectively prevent cisplatin-induced oxidative...
8.
Bao C, Liang S, Han Y, Yang Z, Liu S, Sun Y, et al.
Hypertension
. 2022 Nov;
80(1):70-83.
PMID: 36345832
Background: Autophagy plays an important role in the pathogenesis of pulmonary hypertension (PH). ROC-325 is a novel small molecule lysosomal autophagy inhibitor that has more potent anticancer activity than the...
9.
Jones T, Espitia C, Ooi A, Bauman J, Carew J, Nawrocki S
Cell Death Dis
. 2022 Apr;
13(4):350.
PMID: 35428778
Patients with late-stage and human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) continue to have a very poor prognosis. The development of more effective novel therapies that improve...
10.
Islam S, Espitia C, Persky D, Carew J, Nawrocki S
Viruses
. 2021 Aug;
13(7).
PMID: 34372612
Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus that infects at least 10 million people worldwide and is associated with the development of T-cell lymphoma (TCL). The treatment...